Centessa Pharmaceuticals-adr(CNTA)
$15.99▲2.11%
Market is closed - opens 7 PM, 14 Oct 2024
Insights
- Centessa Pharmaceuticals-adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
- Based on analysis of the Oscillators technical indicator, the current market trend for Centessa Pharmaceuticals-adr stock suggests that it is range bound and no decision can be made based on this information
- Based on analysis of the Moving Averages technical indicator, Centessa Pharmaceuticals-adr stock is in a uptrend ↗️
- Based on analysis of the Pivot Points, the current market trend for Centessa Pharmaceuticals-adr stock suggests that it is a good time to buy
Analysis Summary
Oscillators
Sell
Neutral
Buy
Moving Averages
Sell
Neutral
Buy
Pivots
Sell
Neutral
Buy
Oscillators
Name | Value | Action |
|---|---|---|
Relative Strength Index | 52.24 | Neutral |
Stochastic | 15.18, 22.77 | Neutral |
Ultimate Oscillator | 42.8 | Neutral |
Stochastic Relative Strength Index | 8.9, 6.68 | Buy |
Moving Average Convergence Divergence | 0.53, 0.72 | Sell |
Moving Averages
Simple Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 15.99 | Buy |
20 | 15.96 | Buy |
50 | 13.87 | Buy |
Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 15.86 | Buy |
20 | 15.58 | Buy |
50 | 14.12 | Buy |
Volume Weighted Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 16.1 | Neutral |
20 | 16.08 | Neutral |
50 | 14.74 | Buy |
Double Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 15.92 | Sell |
20 | 16.39 | Buy |
50 | 16.3 | Buy |
Triple Exponential Moving Average
Period (Days) | Value | Action |
|---|---|---|
10 | 15.7 | Sell |
20 | 16.06 | Sell |
50 | 16.93 | Buy |
Pivot
Pivot | Value |
|---|---|
Resistance L3 | 16.9 |
Resistance L2 | 16.5 |
Resistance L1 | 16.29 |
Pivot Point | 15.88 |
Support L1 | 15.67 |
Support L2 | 15.27 |
Support L3 | 15.06 |
*Disclaimer: The content present here is for informational purposes only, you should not construe any such information or other material as investment advisory.